AU2009324371B2 - Antibody formulation - Google Patents

Antibody formulation Download PDF

Info

Publication number
AU2009324371B2
AU2009324371B2 AU2009324371A AU2009324371A AU2009324371B2 AU 2009324371 B2 AU2009324371 B2 AU 2009324371B2 AU 2009324371 A AU2009324371 A AU 2009324371A AU 2009324371 A AU2009324371 A AU 2009324371A AU 2009324371 B2 AU2009324371 B2 AU 2009324371B2
Authority
AU
Australia
Prior art keywords
formulation
antibody
formulations
acz885
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009324371A
Other languages
English (en)
Other versions
AU2009324371A1 (en
Inventor
Joachim Momm
Hans-Joachim Wallny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009324371(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009324371A1 publication Critical patent/AU2009324371A1/en
Application granted granted Critical
Publication of AU2009324371B2 publication Critical patent/AU2009324371B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2009324371A 2008-12-10 2009-12-09 Antibody formulation Active AU2009324371B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884.4 2008-12-10
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (2)

Publication Number Publication Date
AU2009324371A1 AU2009324371A1 (en) 2011-06-23
AU2009324371B2 true AU2009324371B2 (en) 2013-10-10

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324371A Active AU2009324371B2 (en) 2008-12-10 2009-12-09 Antibody formulation

Country Status (31)

Country Link
US (3) US20110236398A1 (enExample)
EP (4) EP2196476A1 (enExample)
JP (5) JP6143416B2 (enExample)
KR (2) KR20170044211A (enExample)
CN (3) CN102245639B (enExample)
AU (1) AU2009324371B2 (enExample)
BR (1) BRPI0922730A2 (enExample)
CA (1) CA2745938C (enExample)
CL (1) CL2011001406A1 (enExample)
CO (1) CO6361952A2 (enExample)
CY (2) CY1117735T1 (enExample)
DK (2) DK3072906T3 (enExample)
EC (1) ECSP11011192A (enExample)
ES (2) ES2579835T3 (enExample)
HR (2) HRP20160754T1 (enExample)
HU (2) HUE056626T2 (enExample)
IL (3) IL264316B2 (enExample)
LT (1) LT3072906T (enExample)
MA (1) MA33023B1 (enExample)
MX (1) MX2011006242A (enExample)
MY (2) MY157772A (enExample)
NZ (1) NZ592918A (enExample)
PE (1) PE20120342A1 (enExample)
PL (2) PL3072906T3 (enExample)
PT (2) PT3072906T (enExample)
RU (2) RU2563179C2 (enExample)
SI (2) SI2376533T1 (enExample)
SM (1) SMT201600222B (enExample)
TN (1) TN2011000229A1 (enExample)
WO (1) WO2010066762A1 (enExample)
ZA (1) ZA201103362B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
SI3345615T1 (sl) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT2616090T (pt) 2010-09-17 2023-10-16 Takeda Pharmaceuticals Co Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
NZ629077A (en) * 2012-03-16 2015-12-24 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
SG10201803778PA (en) * 2012-09-20 2018-06-28 Morphosys Ag Treatment for rheumatoid arthritis
WO2014078502A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160002342A1 (en) 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
BR112017003419A2 (pt) * 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
PL3475303T3 (pl) * 2016-06-27 2021-12-06 Morphosys Ag Formulacje przeciwciała anty-cd19
CA3031346A1 (en) * 2016-07-21 2018-01-25 Novartis Ag Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
MA46334A (fr) * 2016-09-27 2019-08-07 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique liquide
KR102512833B1 (ko) 2016-11-18 2023-03-23 아스텔라스세이야쿠 가부시키가이샤 신규 항인간 MUC1 항체 Fab 프래그먼트
US20190048072A1 (en) * 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111315412A (zh) * 2017-09-13 2020-06-19 诺华股份有限公司 Il-1b结合抗体用于治疗酒精性肝炎的用途
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
CN114652825A (zh) * 2020-12-22 2022-06-24 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP4955185B2 (ja) 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2349779T5 (es) * 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
JP2008528638A (ja) * 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
LT2620450T (lt) * 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006306280B2 (en) 2005-10-26 2010-06-17 Novartis Ag Novel use of IL-1beta compounds
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
UA96473C2 (ru) * 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Also Published As

Publication number Publication date
MY166050A (en) 2018-05-22
MX2011006242A (es) 2011-06-24
IL276622A (en) 2020-09-30
CO6361952A2 (es) 2012-01-20
JP2020203889A (ja) 2020-12-24
LT3072906T (lt) 2021-12-27
WO2010066762A1 (en) 2010-06-17
HRP20211899T1 (hr) 2022-03-04
PL3072906T3 (pl) 2022-01-24
HK1159130A1 (zh) 2012-07-27
PT3072906T (pt) 2021-12-14
ECSP11011192A (es) 2011-08-31
RU2563179C2 (ru) 2015-09-20
TN2011000229A1 (en) 2012-12-17
CN104399076A (zh) 2015-03-11
US20120315285A1 (en) 2012-12-13
CL2011001406A1 (es) 2012-03-30
KR20170044211A (ko) 2017-04-24
CA2745938A1 (en) 2010-06-17
IL212922B (en) 2019-02-28
JP6143416B2 (ja) 2017-06-07
JP7286595B2 (ja) 2023-06-05
ES2900624T3 (es) 2022-03-17
SMT201600222B (it) 2016-08-31
JP2018168158A (ja) 2018-11-01
PT2376533T (pt) 2016-07-13
RU2015132431A3 (enExample) 2018-12-24
RU2011127913A (ru) 2013-01-20
EP3072906A1 (en) 2016-09-28
RU2015132431A (ru) 2018-12-24
IL264316B2 (en) 2024-01-01
EP3072906B1 (en) 2021-09-08
KR101762966B1 (ko) 2017-07-31
US8623367B2 (en) 2014-01-07
ES2579835T3 (es) 2016-08-17
PL2376533T3 (pl) 2016-09-30
HUE028408T2 (en) 2016-12-28
JP2015231997A (ja) 2015-12-24
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
US20110236398A1 (en) 2011-09-29
EP2196476A1 (en) 2010-06-16
CN114225022A (zh) 2022-03-25
JP2023109938A (ja) 2023-08-08
CN104399076B (zh) 2021-09-14
DK3072906T3 (da) 2021-12-13
EP2376533A1 (en) 2011-10-19
EP2376533B1 (en) 2016-03-30
PE20120342A1 (es) 2012-04-24
KR20120009421A (ko) 2012-01-31
SI3072906T1 (sl) 2022-01-31
RU2745601C2 (ru) 2021-03-29
EP3792282A1 (en) 2021-03-17
JP2012511540A (ja) 2012-05-24
CA2745938C (en) 2018-04-24
HRP20160754T1 (hr) 2016-08-12
CY1117735T1 (el) 2017-05-17
CN102245639B (zh) 2014-12-24
AU2009324371A1 (en) 2011-06-23
MA33023B1 (fr) 2012-02-01
HUE056626T2 (hu) 2022-02-28
US20200384108A1 (en) 2020-12-10
IL264316A (en) 2019-02-28
IL212922A0 (en) 2011-07-31
BRPI0922730A2 (pt) 2018-11-06
CN102245639A (zh) 2011-11-16
ZA201103362B (en) 2012-01-25
SI2376533T1 (sl) 2016-07-29
CY1124844T1 (el) 2022-11-25
IL264316B1 (en) 2023-09-01
DK2376533T3 (en) 2016-06-27

Similar Documents

Publication Publication Date Title
AU2009324371B2 (en) Antibody formulation
EP1409018B1 (en) Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
JP2020063261A (ja) ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
US9833410B2 (en) Lyophilized formulation comprising GM-CSF neutralizing compound
KR20200014738A (ko) 안정한 항-osmr 항체 제형
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
HK40041917A (en) Antibody formulation
HK1159130B (en) Antibody formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)